How to appeal a Humana men's sexual health — trt + ed denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for men's sexual health — trt + ed

Cited policy: Humana Aveed (Testosterone Undecanoate IM) + Xyosted (Testosterone Enanthate SC) PA

Adult male meeting AUA 2018 / Endo Society 2018 hypogonadism criteria. Aveed: requires REMS-certified provider + in-office observation 30 min post-injection for POME / anaphylaxis monitoring. Xyosted: weekly SC autoinjector, contraindicated with new-onset hypertension. Trial of preferred T (cypionate IM or topical) often required first.

How Humana denies men's sexual health — trt + ed — and how to counter it

Where Humana pushes back: 1) Use generic cypionate first; 2) REMS burden / PA paperwork; 3) Higher cost not justified.

Counter-arguments that hold up: Aveed (FDA Mar 6 2014, Wang J Endocrinol Invest 2010 / Morgentaler J Sex Med 2014) — q10wk dosing reduces injection burden ~5x vs cypionate q1-2 wk; appropriate when adherence is challenged or peak/trough excursions clinically problematic. REMS for POME is patient safety feature, not denial basis. Xyosted (Kovac J Urol 2017) — weekly SC autoinjector improves adherence + flatter PK than cypionate IM, lower hematocrit excursions; SC self-administration eliminates clinic visits. Document specific failure of preferred formulation: peak/trough symptom variation, hematocrit excursions on cypionate, adherence failure with q1-2wk schedule, or transdermal transfer-risk concern.

What Humana typically denies for men's sexual health — trt + ed

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For men's sexual health — trt + ed, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the men's sexual health — trt + ed treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Testosterone cypionate
• Testosterone enanthate
• Aveed (TU IM)
• Xyosted (TE SC)
• Testosterone gel
• Axiron (T solution)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.